7590. Telacebec (Q203), a New Antituberculosis Agent.
作者: Veronique R de Jager.;Rodney Dawson.;Christo van Niekerk.;Jane Hutchings.;Jeongjun Kim.;Naadira Vanker.;Lize van der Merwe.;Jinho Choi.;Kiyean Nam.;Andreas H Diacon.
来源: N Engl J Med. 2020年382卷13期1280-1281页 7598. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
作者: Michael Kozal.;Judith Aberg.;Gilles Pialoux.;Pedro Cahn.;Melanie Thompson.;Jean-Michel Molina.;Beatriz Grinsztejn.;Ricardo Diaz.;Antonella Castagna.;Princy Kumar.;Gulam Latiff.;Edwin DeJesus.;Mark Gummel.;Margaret Gartland.;Amy Pierce.;Peter Ackerman.;Cyril Llamoso.;Max Lataillade.; .
来源: N Engl J Med. 2020年382卷13期1232-1243页
Among some patients with human immunodeficiency virus type 1 (HIV-1) infection who have undergone multiple antiretroviral therapies and have limited options for treatment, new classes of antiretroviral drugs with novel mechanisms of action are needed. Fostemsavir is the prodrug of temsavir, a first-in-class investigational HIV-1 attachment inhibitor.
7599. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
作者: M Domenica Cappellini.;Vip Viprakasit.;Ali T Taher.;Pencho Georgiev.;Kevin H M Kuo.;Thomas Coates.;Ersi Voskaridou.;Hong-Keng Liew.;Idit Pazgal-Kobrowski.;G L Forni.;Silverio Perrotta.;Abderrahim Khelif.;Ashutosh Lal.;Antonis Kattamis.;Efthymia Vlachaki.;Raffaella Origa.;Yesim Aydinok.;Mohamed Bejaoui.;P Joy Ho.;Lee-Ping Chew.;Ping-Chong Bee.;Soo-Min Lim.;Meng-Yao Lu.;Adisak Tantiworawit.;Penka Ganeva.;Liana Gercheva.;Farrukh Shah.;Ellis J Neufeld.;Alexis Thompson.;Abderrahmane Laadem.;Jeevan K Shetty.;Jun Zou.;Jennie Zhang.;Dimana Miteva.;Tatiana Zinger.;Peter G Linde.;Matthew L Sherman.;Olivier Hermine.;John Porter.;Antonio Piga.; .
来源: N Engl J Med. 2020年382卷13期1219-1231页
Patients with transfusion-dependent β-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients.
|